XFORX4 Pharmaceuticals, Incvs its industry peers
A metric-by-metric comparison of X4 Pharmaceuticals, Inc against Biological Products, (No Diagnostic Substances) — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| XFORThis | $311M#9 | 2.2x#1 | 2.0x#10 | 8.9x#3 | 1273.2%#2 | -111.5%#12 | -247.4%#3 | -50.9%#7 | -582.0%#4 | — | -20.6%#11 | — |
| ALLO | $390M#1 | — | 0.9x#2 | — | -100.0%#9 | 25.9%#5 | — | -43.8%#6 | — | — | 3.2%#8 | — |
| ZURA | $383M#2 | — | 3.8x#11 | — | — | -31.0%#11 | — | -67.6%#8 | — | — | 15.5%#7 | — |
| TECX | $380M#3 | — | 1.7x#8 | — | — | -27.9%#10 | — | -33125.9%#12 | -713.5%#5 | — | 15.9%#6 | — |
| CCCC | $373M#4 | — | 1.5x#6 | 10.4x#4 | 1.0%#6 | 0.3%#6 | -320.5%#5 | -42.5%#4 | — | — | 34.9%#5 | — |
| SRZN | $363M#5 | — | — | 104.3x#8 | -67.4%#8 | -280.8%#14 | -1210.6%#6 | — | — | — | 120.4%#2 | — |
| KYTX | $313M#6 | — | 1.9x#9 | — | — | -26.5%#9 | — | -97.4%#10 | -107.1%#3 | — | -20.1%#10 | — |
| SCTX | $311M#7 | — | — | — | — | — | — | — | — | — | — | — |
| AGEN | $311M#8 | 2.3x#2 | — | 2.7x#2 | 10.4%#4 | 98.7%#2 | -17.7%#2 | — | — | — | 85.4%#3 | — |
| SABS | $298M#10 | 13.7x#3 | 1.4x#5 | — | -100.0%#9 | 138.9%#1 | — | 6.2%#1 | — | — | 0.9%#9 | — |
| IPSC | $297M#11 | — | 1.3x#4 | 2.7x#1 | 1556.8%#1 | 92.4%#3 | -15.8%#1 | -4.1%#3 | -9.3%#1 | — | 187.6%#1 | — |
| EIKN | $292M#12 | — | 0.6x#1 | — | — | — | — | 0.0%#2 | — | — | — | — |
| OCGN | $271M#13 | — | — | 61.3x#7 | 8.8%#5 | -25.9%#8 | -1425.7%#7 | — | — | — | -44.0%#13 | — |
| LXEO | $264M#15 | — | 1.1x#3 | 404.0x#9 | — | -1.7%#7 | -16706.0%#9 | -42.5%#5 | — | — | -61.4%#14 | — |
| LCTX | $264M#14 | — | 4.3x#12 | 18.2x#5 | 53.2%#3 | -241.4%#13 | -251.6%#4 | -104.3%#11 | — | — | -42.4%#12 | — |
| FATE | $246M#16 | — | 1.6x#7 | 37.0x#6 | -51.2%#7 | 26.8%#4 | -2222.4%#8 | -88.8%#9 | -102.3%#2 | — | 71.5%#4 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-11-04.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice